Progynova is equivalent to natural 17 β-estradiol which is found in Estrace. Estrace contains micronized 17 β-estradiol. It is generally well-tolerated, and clinical data from postmenopausal women suggest it is safer than ethinyloestradiol for long-term use, with less risk of breast cancer, thromboembolic events or liver problems.
Main Use
Climacteric complaints after cessation of monthly bleeding or deficiency symptoms after oophorectomy or radiological castration for non-carcinomatous diseases, such as hot flushes, outbreaks of sweat, sleep disturbances, depressive moods, irritability, headaches, dizziness, bladder irritation, signs of muco-cutaneous involution.
Dosage and Administration
Before starting Progynova, a thorough general medical and gynaecological examination (including the breasts and a cytological smear of the cervix) should be carried out.
As a precaution, clinical follow-up should be conducted at intervals of about 6 months.
1 tablet Progynova 2 mg is taken daily after a meal. The tablets are to be swallowed whole with some liquid. The treatment is continuous. The next pack follows immediately without a break.
In the course of treatment, the dosage may be reduced to 1 tablet Progynova, 1 mg daily.
| 
